drugset / Trial / NCT02086188

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if treatment with Mirabegron will improve urinary urgency control beyond that achieved with pelvic floor exercises alone

Timeline

Start
2014-05
Primary completion
2019-04
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg Oral
Subject Mirabegron Other / unclassified 50 mg Oral

Indications